Table 1.

Baseline characteristics of patients and catheters by treatment group

CharacteristicTreatment groupPvaluea
HeparinHeparin and vancomycin
Sex (no. [%] of patients)
 Male39 (68.4)31 (51.7)0.07
 Female18 (31.6)29 (48.3)
Age
 Mean (yr)44420.5b
 Median (yr)4740
Tertiles (no. [%] of patients)
  ≤3014 (24.6)23 (38.3)0.2
  31–5224 (42.1)17 (28.3)
  ≥5319 (33.3)20 (33.3)
Underlying disease (no. [%] of patients)c
 AML37 (64.9)33 (55.0)0.8
 CML6 (10.5)10 (16.7)
 ALL8 (14.0)9 (15.0)
 NHL4 (7.0)5 (8.3)
 HD2 (3.5)3 (5.0)
Type of catheter (no. [%] of patients)
 Double lumen35 (61.4)40 (66.7)0.6
 Triple lumen22 (38.6)20 (33.3)
Duration of catheterization prior to randomization (days)
 Mean24250.9b
 Median1010
  • a P values are from the chi-square test or Fisher’s exact test unless otherwise indicated.

  • b P values are from the Mann-Whitney test.

  • c AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphocytic leukemia; NHL, non-Hodgkin’s lymphoma; HD, Hodgkin’s disease.